Overview

Diamine Oxidase (DAO) is a copper-containing enzyme responsible for the oxidative deamination of histamine and other biogenic amines including putrescine, cadaverine, and spermidine. Research indicates DAO plays critical roles in maintaining histamine homeostasis, regulating immune responses, and protecting intestinal barrier function.

Studies suggest that DAO deficiency or dysfunction may contribute to histamine intolerance, chronic urticaria, inflammatory bowel conditions, and various immune-mediated disorders. The enzyme is primarily produced in the intestinal mucosa, kidneys, and placenta, with serum levels serving as potential biomarkers for intestinal health and inflammatory states.

Recent research has identified DAO as a novel mediator of inflammatory responses through its effects on NK cell function and the "cytosolic ROS-autophagy-IFN-γ" axis, suggesting broader therapeutic potential beyond histamine metabolism.

Mechanism of Action

DAO catalyzes the oxidative deamination of histamine and other diamines through a copper-dependent mechanism involving topaquinone cofactor. The enzyme converts histamine to imidazole acetaldehyde, hydrogen peroxide, and ammonia, effectively reducing histamine levels in tissues and circulation.

Research suggests DAO functions through several key pathways:

Histamine Degradation: Primary mechanism involves oxidative metabolism of histamine, reducing local and systemic histamine burden and associated inflammatory responses.

NK Cell Regulation: Recent studies indicate DAO mediates NK cell function through modulation of cytosolic ROS levels, autophagy pathways, and IFN-γ production, influencing immune surveillance and inflammatory responses.

Intestinal Homeostasis: DAO appears to maintain intestinal barrier function and mucosal integrity, with levels correlating with intestinal health status and inflammatory conditions.

Vascular Function: The enzyme may regulate vascular inflammation through its role as vascular adhesion protein-1 (VAP-1), affecting leukocyte trafficking and endothelial function.

Research Summary

10 papers found on PubMed examining DAO's roles in immune function, inflammation, and therapeutic applications. 5 clinical trials are investigating DAO-related interventions in various conditions including ICU patients, histamine intolerance, and cirrhosis.

Key Studies

Immune Regulation (2025) A recent study in Life Sciences demonstrated that DAO acts as a novel risk factor in abnormal inflammation by mediating the "cytosolic ROS-autophagy-IFN-γ" axis in NK cells. This research revealed new mechanisms by which DAO influences immune responses beyond histamine metabolism.

Recombinant Production (2016) Research in Journal of Biotechnology characterized recombinant human DAO produced in Chinese Hamster Ovary cells, establishing protocols for therapeutic enzyme production and demonstrating maintained enzymatic activity and stability.

Chronic Urticaria (2015) A study in Allergologia et Immunopathologia examined DAO levels across different chronic urticaria phenotypes, finding correlations between enzyme levels and disease severity, suggesting potential diagnostic and therapeutic applications.

Intestinal Function (2024) FASEB Journal research demonstrated DAO's role in intestinal homeostasis and acute pancreatitis, showing that intestinal DAO levels correlate with barrier function and inflammatory status.

Gut Microbiota Interactions (2022) Medicine journal findings revealed alterations in gut microbiota and cytokines in patients with elevated serum DAO levels, suggesting complex interactions between enzyme activity, microbiome, and immune function.

Dosage Guidelines

Therapeutic dosing protocols for DAO supplementation are not yet established in human studies. Research applications have used varying concentrations of recombinant enzyme:

Current clinical trials are investigating DAO-related interventions, but specific dosing recommendations await completion of human studies.

Safety Profile

Safety data for therapeutic DAO administration is limited to preclinical studies and case reports. The enzyme is naturally produced in the human body, suggesting potential for good tolerability, but several considerations apply:

Potential Concerns:

• Copper metabolism effects due to copper cofactor requirement
• Immune modulation effects through NK cell pathway interactions
• Unknown long-term effects of exogenous enzyme supplementation
• Potential allergic reactions to recombinant protein

Monitoring Recommendations:

• Copper status assessment before and during treatment
• Complete blood count to monitor immune cell populations
• Liver function tests due to hepatic elimination
• Histamine and DAO serum levels to assess therapeutic response

Contraindicated Conditions: Research suggests avoiding DAO supplementation in patients with copper metabolism disorders, active malignancy, pregnancy, or pediatric populations due to insufficient safety data.

Stacking

DAO stacking protocols are theoretical and based on enzymatic requirements and metabolic pathways:

Copper Support: Adequate copper status is essential for DAO enzymatic activity. Copper-containing compounds or ensuring adequate dietary copper may support enzyme function.

Histamine-Related Compounds: DAO may be combined with other histamine-modulating interventions, though careful monitoring is required to avoid excessive histamine suppression.

Immune Modulators: Given DAO's effects on NK cell function and inflammatory pathways, stacking with immune modulators requires careful consideration of cumulative effects.

Current evidence is insufficient to recommend specific stacking protocols. Future research may establish safe and effective combination approaches for histamine intolerance and inflammatory conditions.

References

1. Diamine oxidase acts as a novel risk factor in abnormal inflammation via mediating "cytosolic ROS-autophagy-IFN-γ" axis in NK cells. (2025). Life sciences. DOI PubMed
2. Vascular adhesion protein-1 (VAP-1) in vascular inflammatory diseases. (2022). VASA. Zeitschrift fur Gefasskrankheiten. DOI PubMed
3. Diamine oxidase levels in different chronic urticaria phenotypes. (2015). Allergologia et immunopathologia. DOI PubMed
4. Inhibition of Pck1 in intestinal epithelial cells alleviates acute pancreatitis via modulating intestinal homeostasis. (2024). FASEB journal : official publication of the Federation of American Societies for Experimental Biology. DOI PubMed
5. Characterization of recombinant human diamine oxidase (rhDAO) produced in Chinese Hamster Ovary (CHO) cells. (2016). Journal of biotechnology. DOI PubMed
6. Primary structure of a pyrroloquinoline quinone (PQQ) containing peptide isolated from porcine kidney diamine oxidase. (1989). Biochemical and biophysical research communications. DOI PubMed
7. Alterations of gut microbiota and cytokines in elevated serum diamine oxidase disorder. (2022). Medicine. DOI PubMed
8. Lathyrus sativus diamine oxidase reduces Clostridium difficile toxin A-induced toxicity in Caco-2 cells by rescuing RhoA-GTPase and inhibiting pp38-MAPK/NF-κB/HIF-1α activation. (2021). Phytotherapy research : PTR. DOI PubMed
9. Gallium-labelled peptides for imaging of inflammation. (2012). European journal of nuclear medicine and molecular imaging. DOI PubMed
10. Analysis of mast cell activation using diamine oxidase-gold enzyme-affinity ultrastructural cytochemistry. (1995). International archives of allergy and immunology. DOI PubMed